Clinical Trial
Cytokine-release syndrome: differences between high and low doses of OKT3
Affiliations
- PMID: 8465420
Item in Clipboard
Clinical Trial
Cytokine-release syndrome: differences between high and low doses of OKT3
Transplant Proc.
1993 Apr.
No abstract available
Similar articles
-
Five-year experience with a triple drug protocol in renal transplantation.Transplant Proc. 1992 Feb;24(1):56-7. Transplant Proc. 1992. PMID: 1539342 No abstract available.
-
Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.Transplant Proc. 1992 Feb;24(1):39-41. Transplant Proc. 1992. PMID: 1539329 Clinical Trial. No abstract available.
-
Renal allograft rejection in a patient with the Wiskott-Aldrich syndrome.Transplantation. 1995 Apr 27;59(8):1214-5. Transplantation. 1995. PMID: 7732568 No abstract available.
-
OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).Transplant Proc. 1993 Apr;25(2 Suppl 1):25-6. Transplant Proc. 1993. PMID: 8465417 Review. No abstract available.
-
[Immunosuppressive therapy].Rinsho Byori. 1991 Jul;Suppl 90:102-14. Rinsho Byori. 1991. PMID: 1920848 Review. Japanese. No abstract available.
Cited by
-
Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.Drug Saf. 1999 Dec;21(6):471-88. doi: 10.2165/00002018-199921060-00004. Drug Saf. 1999. PMID: 10612271 Review.
-
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.Cochrane Database Syst Rev. 2017 Jan 11;1(1):CD004759. doi: 10.1002/14651858.CD004759.pub2. Cochrane Database Syst Rev. 2017. PMID: 28073178 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical